Morphine

證據等級: L5

預測適應症: 10 個

Morphine: From Pain Management to Myofascial Pain Syndrome

One-Sentence Summary

Morphine is a mu-opioid receptor agonist long established for moderate-to-severe pain. The TxGNN model predicts it may be effective for Myofascial Pain Syndrome (MPS), with 33 clinical trials and 17 publications identified, though the evidence is largely class-level (opioids in chronic pain generally) rather than morphine-specific trials in MPS.

Quick Overview

Item	Content
Original Indication	Moderate to severe pain (opioid analgesic) — no matching TGA/ARTG licence text was returned by this query
Predicted New Indication	Myofascial Pain Syndrome
TxGNN Prediction Score	99.75%
Evidence Level	L3
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed TGA-registered mechanism-of-action data is not available for this candidate (data gap). Based on established pharmacology, morphine is a mu-opioid receptor agonist that produces analgesia through spinal and supraspinal inhibition of nociceptive transmission — a broad-spectrum analgesic mechanism rather than a disease-specific one.

Myofascial Pain Syndrome is itself a chronic pain condition involving muscle trigger points and central sensitisation, so there is a plausible mechanistic extension from morphine’s general analgesic action to MPS. However, the identified evidence base largely consists of studies on opioids in chronic non-cancer pain as a drug class (e.g., long-term opioid therapy registries, opioid-sparing strategies after surgery) and trigger-point-focused procedural trials, rather than trials testing morphine specifically against MPS as a primary endpoint.

Given that opioids are not recommended as first-line therapy for chronic non-cancer pain conditions such as MPS under most current clinical guidelines, this prediction should be regarded as a research hypothesis for further mechanistic and clinical investigation rather than an established therapeutic pathway.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT06955923	Phase 2	Completed	11	Trigger point injections immediately post-TKA vs sham, evaluating pain scores and opioid use; notes correlation between soft-tissue manipulation and myofascial pain
NCT04640896	Phase 4	Recruiting	60	Trigger point injections vs traditional therapy for postsurgical cervical myofascial pain after anterior cervical spine surgery
NCT03161795	N/A	Completed	258	Multicentre South Korean observational study on risks of long-term opioid therapy in chronic non-cancer pain, including opioid-related chemical coping
NCT03271151	Phase 4	Completed	160	Double-blind RCT of duloxetine’s effect on opioid consumption after total knee arthroplasty
NCT04504812	Phase 3	Completed	1937	Large effectiveness trial comparing treatments to reduce opioid reliance and improve pain/function in knee osteoarthritis
NCT06533345	N/A	Recruiting	120	Chronic pain research clinic examining neuropathic, structural and nociplastic (e.g., fibromyalgia-type) pain mechanisms and treatment
NCT05069363	N/A	Recruiting	20	Feasibility trial of whole-body photobiomodulation for chronic pain, referencing morphine as a current but often inadequate treatment option
NCT04862845	Phase 1	Completed	90	Multimodal analgesia (duloxetine + pregabalin) to reduce opioid reliance after liposuction surgery
NCT04090099	N/A	Completed	93	Regional nerve blocks vs opioid-based analgesia after cardiac surgery, highlighting opioid-related adverse effects
NCT05050656	Phase 4	Completed	70	Duloxetine premedication and its effect on postoperative pain control after ACL repair under spinal anaesthesia

Note: Most trials returned by the underlying knowledge-graph search relate to opioids as a drug class in chronic/postoperative pain, or to non-pharmacological/procedural MPS treatments (dry needling, trigger point injection), rather than morphine tested specifically against MPS. Several additional low-relevance trials (e.g., rTMS, tDCS, cryoanalgesia device studies unrelated to opioid pharmacology) were excluded from this table.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
41664327	2026	RCT	Asian Spine Journal	Double-blind RCT comparing dexmedetomidine + morphine vs plain ropivacaine for myofascial infiltration in thoracolumbar spinal fusion
22648287	2012	Cohort	Journal of Anesthesia	Cervical facet joint injections added to multimodal treatment for long-standing cervical myofascial pain syndrome
35066974	2022	Cohort	Pain Practice	Structured stretching exercise programme and its effect on resolving myofascial pain and reducing opioid use in “legacy pain” patients
20390305	2010	Cohort	Der Schmerz	Altered pain thresholds during and after opioid withdrawal in patients with chronic low back pain
21419546	2011	Review	J Oral Maxillofac Surg	Review of long-term opioid use in chronic temporomandibular joint dysfunction
16713811	2006	Review	J Oral Maxillofac Surg	Arthrocentesis with intra-articular morphine infusion for refractory TMJ pain dysfunction syndrome
17870625	2008	Comparative trial	European Journal of Pain	Epidural analgesia vs intercostal nerve cryoanalgesia for post-thoracotomy pain control
21691691	2011	Descriptive study	Rev Assoc Med Bras	Therapeutic approach in 56 patients with failed back surgery pain syndrome
39793344	2025	Study (type pending)	Eur J Obstet Gynecol Reprod Biol	Pudendal nerve block for perioperative pain after botulinum toxin injection for myofascial pelvic pain
16967674	2006	Review	J Calif Dent Assoc	Use of oral medications, infusions and injections in differential diagnosis of orofacial pain

Australia Market Information

No ARTG entries were returned for this candidate in the current dataset (0 licences; market status: not marketed). This is a data gap in the underlying regulatory query rather than confirmation that no morphine products exist on the Australian market — morphine is a Schedule 8 (Controlled Drug) opioid with a long history of clinical use, and TGA/ARTG records should be checked directly to confirm current registered products, formulations and approved indications before any repurposing evaluation proceeds.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. No structured warnings, contraindications or drug interaction data were returned in this evidence pack (DDI query: not found).

As general clinical context worth flagging: several of the trials and literature above indicate that opioids are associated with dependence risk, opioid-induced hyperalgesia, and are generally positioned as third-line or adjunct therapy — not first-line — in chronic non-cancer pain conditions similar to MPS. This should be weighed heavily in any Australian PI safety review.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction score is high, but the supporting evidence is class-level (opioids broadly in chronic/postoperative pain) rather than morphine-specific trials for MPS, and the underlying scoring itself flags this as a “Research Question” at an early evaluation stage (L3/S1). Given morphine’s opioid dependence and misuse risk, and that current guidelines do not support opioids as first-line MPS therapy, clinical progression is not warranted on the present evidence.

To proceed, the following is needed:

TGA-approved Product Information (warnings, contraindications, DDI) — currently a blocking data gap for safety assessment
Confirmed mechanism-of-action documentation (DrugBank or TGA source) — currently a data gap
A dedicated trial testing morphine (or opioids as a class) specifically against MPS outcomes, rather than general chronic-pain opioid-use data
Confirmation of current ARTG registration status and available formulations in Australia
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.